103502-23-4

Upstream product

• 14374-54-0 5-(4-methoxyphenyl)pentan-1-ol 
• 1145779-11-8 1-methoxy-4-[(1Z)-5-phenoxypent-1-en-1-yl]benzene 
• 1004304-59-9 1-(4-methoxyphenyl)-5-phenoxypentane 

Downstream Products

• 1004304-77-1 5-bromo-1-(4-benzyloxyphenyl)pentane 
• 4729-21-9 dispiro<5,5>undeca-1,4-dien-3-one 

Relevant academic research and scientific papers

Sulfonyl fluoride inhibitors of fatty acid amide hydrolase

Sulfonyl fluorides are known to inhibit esterases. Early work from our laboratory has identified hexadecyl sulfonylfluoride (AM374) as a potent in vitro and in vivo inhibitor of fatty acid amide hydrolase (FAAH). We now report on later generation sulfonyl

DUAL MODULATION OF ENDOCANNABINOID TRANSPORT AND FATTY-ACID AMIDE HYDROLASE FOR TREATMENT OF EXCITOTOXICITY

The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor.Disruption of such signals has been shown to prevent neuronal maintenance processes and increase vulnerability to brain damage. Here, blocking endocannabinoid inactivation enhanced cannabinergic activity and ameliorated cellular disturbances associated with excitotoxicity. Modulating the endocannabinoid system in this way also prevented excitotoxic behavioral abnormalities including memory impairment. Collectively, these results indicate that increasing endocannabinoid responses by inhibiting the endocannabinoid transported and/or the inhibiting FAAH leads to molecular, cellular, and functional protection against excitotoxic insults like stroke and traumatic brain injury.

MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY

Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.